2.Therapeutic options for management of endometrial hyperplasia.
Vishal CHANDRA ; Jong Joo KIM ; Doris Mangiaracina BENBROOK ; Anila DWIVEDI ; Rajani RAI
Journal of Gynecologic Oncology 2016;27(1):e8-
		                        		
		                        			
		                        			Endometrial hyperplasia (EH) comprises a spectrum of changes in the endometrium ranging from a slightly disordered pattern that exaggerates the alterations seen in the late proliferative phase of the menstrual cycle to irregular, hyperchromatic lesions that are similar to endometrioid adenocarcinoma. Generally, EH is caused by continuous exposure of estrogen unopposed by progesterone, polycystic ovary syndrome, tamoxifen, or hormone replacement therapy. Since it can progress, or often occur coincidentally with endometrial carcinoma, EH is of clinical importance, and the reversion of hyperplasia to normal endometrium represents the key conservative treatment for prevention of the development of adenocarcinoma. Presently, cyclic progestin or hysterectomy constitutes the major treatment option for EH without or with atypia, respectively. However, clinical trials of hormonal therapies and definitive standard treatments remain to be established for the management of EH. Moreover, therapeutic options for EH patients who wish to preserve fertility are challenging and require nonsurgical management. Therefore, future studies should focus on evaluation of new treatment strategies and novel compounds that could simultaneously target pathways involved in the pathogenesis of estradiol-induced EH. Novel therapeutic agents precisely targeting the inhibition of estrogen receptor, growth factor receptors, and signal transduction pathways are likely to constitute an optimal approach for treatment of EH.
		                        		
		                        		
		                        		
		                        			Antineoplastic Agents, Hormonal/adverse effects
		                        			;
		                        		
		                        			Disease Management
		                        			;
		                        		
		                        			Disease Progression
		                        			;
		                        		
		                        			Endometrial Hyperplasia/classification/etiology/*therapy
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Gonadotropin-Releasing Hormone/therapeutic use
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy
		                        			;
		                        		
		                        			Molecular Targeted Therapy/methods
		                        			;
		                        		
		                        			Progesterone Congeners/therapeutic use
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Tamoxifen/adverse effects
		                        			
		                        		
		                        	
3.Robotic single site versus robotic multiport hysterectomy in early endometrial cancer: a case control study.
Giacomo CORRADO ; Giuseppe CUTILLO ; Emanuela MANCINI ; Ermelinda BAIOCCO ; Lodovico PATRIZI ; Maria SALTARI ; Anna DI LUCA SIDOZZI ; Isabella SPERDUTI ; Giulia POMATI ; Enrico VIZZA
Journal of Gynecologic Oncology 2016;27(4):e39-
		                        		
		                        			
		                        			OBJECTIVE: To compare surgical outcomes and cost of robotic single-site hysterectomy (RSSH) versus robotic multiport hysterectomy (RMPH) in early stage endometrial cancer. METHODS: This is a retrospective case-control study, comparing perioperative outcomes and costs of RSSH and RMPH in early stage endometrial cancer patients. RSSH were matched 1:2 according to age, body mass index, comorbidity, the International Federation of Gynecology and Obstetric (FIGO) stage, type of radical surgery, histologic type, and grading. Mean hospital cost per discharge was calculated summarizing the cost of daily hospital room charges, operating room, cost of supplies and length of hospital stay. RESULTS: A total of 23 women who underwent RSSH were matched with 46 historic controls treated by RMPH in the same institute, with the same surgical team. No significant differences were found in terms of age, histologic type, stage, and grading. Operative time was similar: 102.5 minutes in RMPH and 110 in RSSH (p=0.889). Blood loss was lower in RSSH than in RMPH (respectively, 50 mL vs. 100 mL, p=0.001). Hospital stay was 3 days in RMPH and 2 days in RSSH (p=0.001). No intraoperative complications occurred in both groups. Early postoperative complications were 2.2% in RMPH and 4.3% in RSSH. Overall cost was higher in RMPH than in RSSH (respectively, $7,772.15 vs. $5,181.06). CONCLUSION: Our retrospective study suggests the safety and feasibility of RSSH for staging early endometrial cancer without major differences from the RMPH in terms of surgical outcomes, but with lower hospital costs. Certainly, further studies are eagerly warranted to confirm our findings.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Case-Control Studies
		                        			;
		                        		
		                        			Endometrial Neoplasms/economics/*surgery
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Health Care Costs
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy/adverse effects/*methods
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Postoperative Complications/epidemiology
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Robotic Surgical Procedures/adverse effects/economics/*methods
		                        			
		                        		
		                        	
4.Robotic single site versus robotic multiport hysterectomy in early endometrial cancer: a case control study.
Giacomo CORRADO ; Giuseppe CUTILLO ; Emanuela MANCINI ; Ermelinda BAIOCCO ; Lodovico PATRIZI ; Maria SALTARI ; Anna DI LUCA SIDOZZI ; Isabella SPERDUTI ; Giulia POMATI ; Enrico VIZZA
Journal of Gynecologic Oncology 2016;27(4):e39-
		                        		
		                        			
		                        			OBJECTIVE: To compare surgical outcomes and cost of robotic single-site hysterectomy (RSSH) versus robotic multiport hysterectomy (RMPH) in early stage endometrial cancer. METHODS: This is a retrospective case-control study, comparing perioperative outcomes and costs of RSSH and RMPH in early stage endometrial cancer patients. RSSH were matched 1:2 according to age, body mass index, comorbidity, the International Federation of Gynecology and Obstetric (FIGO) stage, type of radical surgery, histologic type, and grading. Mean hospital cost per discharge was calculated summarizing the cost of daily hospital room charges, operating room, cost of supplies and length of hospital stay. RESULTS: A total of 23 women who underwent RSSH were matched with 46 historic controls treated by RMPH in the same institute, with the same surgical team. No significant differences were found in terms of age, histologic type, stage, and grading. Operative time was similar: 102.5 minutes in RMPH and 110 in RSSH (p=0.889). Blood loss was lower in RSSH than in RMPH (respectively, 50 mL vs. 100 mL, p=0.001). Hospital stay was 3 days in RMPH and 2 days in RSSH (p=0.001). No intraoperative complications occurred in both groups. Early postoperative complications were 2.2% in RMPH and 4.3% in RSSH. Overall cost was higher in RMPH than in RSSH (respectively, $7,772.15 vs. $5,181.06). CONCLUSION: Our retrospective study suggests the safety and feasibility of RSSH for staging early endometrial cancer without major differences from the RMPH in terms of surgical outcomes, but with lower hospital costs. Certainly, further studies are eagerly warranted to confirm our findings.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Case-Control Studies
		                        			;
		                        		
		                        			Endometrial Neoplasms/economics/*surgery
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Health Care Costs
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy/adverse effects/*methods
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Postoperative Complications/epidemiology
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Robotic Surgical Procedures/adverse effects/economics/*methods
		                        			
		                        		
		                        	
5.Conventional versus nerve-sparing radical surgery for cervical cancer: a meta-analysis.
Hee Seung KIM ; Keewon KIM ; Seung Bum RYOO ; Joung Hwa SEO ; Sang Youn KIM ; Ji Won PARK ; Min A KIM ; Kyoung Sup HONG ; Chang Wook JEONG ; Yong Sang SONG
Journal of Gynecologic Oncology 2015;26(2):100-110
		                        		
		                        			
		                        			OBJECTIVE: Although nerve-sparing radical surgery (NSRS) is an emerging technique for reducing surgery-related dysfunctions, its efficacy is controversial in patients with cervical cancer. Thus, we performed a meta-analysis to compare clinical outcomes, and urinary, anorectal, and sexual dysfunctions between conventional radical surgery (CRS) and NSRS. METHODS: After searching PubMed, Embase, and the Cochrane Library, two randomized controlled trials, seven prospective and eleven retrospective cohort studies were included with 2,253 patients from January 2000 to February 2014. We performed crude analyses and then conducted subgroup analyses according to study design, quality of study, surgical approach, radicality, and adjustment for potential confounding factors. RESULTS: Crude analyses showed decreases in blood loss, hospital stay, frequency of intraoperative complications, length of the resected vagina, duration of postoperative catheterization (DPC), urinary frequency, and abnormal sensation in NSRS, whereas there were no significant differences in other clinical parameters and dysfunctions between CRS and NSRS. In subgroup analyses, operative time was longer (standardized difference in means, 0.948; 95% confidence interval [CI], 0.642 to 1.253), while intraoperative complications were less common (odds ratio, 0.147; 95% CI, 0.035 to 0.621) in NSRS. Furthermore, subgroup analyses showed that DPC was shorter, urinary incontinence or frequency, and constipation were less frequent in NSRS without adverse effects on survival and sexual functions. CONCLUSION: NSRS may not affect prognosis and sexual dysfunctions in patients with cervical cancer, whereas it may decrease intraoperative complications, and urinary and anorectal dysfunctions despite long operative time and short length of the resected vagina when compared with CRS.
		                        		
		                        		
		                        		
		                        			Constipation/epidemiology/etiology
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy/adverse effects/*methods
		                        			;
		                        		
		                        			Intraoperative Complications/epidemiology
		                        			;
		                        		
		                        			*Organ Sparing Treatments/adverse effects/methods
		                        			;
		                        		
		                        			Pelvis/*innervation/surgery
		                        			;
		                        		
		                        			Rectum/*innervation/surgery
		                        			;
		                        		
		                        			Sexual Dysfunction, Physiological/epidemiology/etiology
		                        			;
		                        		
		                        			Urinary Bladder/*innervation/surgery
		                        			;
		                        		
		                        			Urinary Retention/epidemiology/etiology
		                        			;
		                        		
		                        			Uterine Cervical Neoplasms/epidemiology/*surgery
		                        			;
		                        		
		                        			Uterus/innervation/surgery
		                        			;
		                        		
		                        			Vagina/innervation/surgery
		                        			
		                        		
		                        	
6.Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial.
Ju Won ROH ; Dong Ock LEE ; Dong Hoon SUH ; Myong Cheol LIM ; Sang Soo SEO ; Jinsoo CHUNG ; Sun LEE ; Sang Yoon PARK
Journal of Gynecologic Oncology 2015;26(2):90-99
		                        		
		                        			
		                        			OBJECTIVE: A prospective, randomized controlled trial was conducted to evaluate the efficacy of nerve-sparing radical hysterectomy (NSRH) in preserving bladder function and its oncologic safety in the treatment of cervical cancer. METHODS: From March 2003 to November 2005, 92 patients with cervical cancer stage IA2 to IIA were randomly assigned for surgical treatment with conventional radical hysterectomy (CRH) or NSRH, and 86 patients finally included in the analysis. Adequacy of nerve sparing, radicality, bladder function, and oncologic safety were assessed by quantifying the nerve fibers in the paracervix, measuring the extent of paracervix and harvested lymph nodes (LNs), urodynamic study (UDS) with International Prostate Symptom Score (IPSS), and 10-year disease-free survival (DFS), respectively. RESULTS: There were no differences in clinicopathologic characteristics between two groups. The median number of nerve fiber was 12 (range, 6 to 21) and 30 (range, 17 to 45) in the NSRH and CRH, respectively (p<0.001). The extent of resected paracervix and number of LNs were not different between the two groups. Volume of residual urine and bladder compliance were significantly deteriorated at 12 months after CRH. On the contrary, all parameters of UDS were recovered no later than 3 months after NSRH. Evaluation of the IPSS showed that the frequency of long-term urinary symptom was higher in CRH than in the NSRH group. The median duration before the postvoid residual urine volume became less than 50 mL was 11 days (range, 7 to 26 days) in NSRH group and was 18 days (range, 10 to 85 days) in CRH group (p<0.001). No significant difference was observed in the 10-year DFS between two groups. CONCLUSION: NSRH appears to be effective in preserving bladder function without sacrificing oncologic safety.
		                        		
		                        		
		                        		
		                        			Adenocarcinoma/mortality/pathology/surgery
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Carcinoma, Adenosquamous/mortality/pathology/surgery
		                        			;
		                        		
		                        			Carcinoma, Squamous Cell/mortality/pathology/surgery
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy/adverse effects/*methods
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			*Organ Sparing Treatments/adverse effects/methods
		                        			;
		                        		
		                        			Pelvis/*innervation/surgery
		                        			;
		                        		
		                        			Recovery of Function
		                        			;
		                        		
		                        			Survival Analysis
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Urinary Bladder/*innervation/physiology/surgery
		                        			;
		                        		
		                        			Uterine Cervical Neoplasms/mortality/pathology/*surgery
		                        			;
		                        		
		                        			Uterus/*innervation/surgery
		                        			
		                        		
		                        	
7.The Korean guideline for cervical cancer screening.
Kyung Jin MIN ; Yoon Jae LEE ; Mina SUH ; Chong Woo YOO ; Myong Cheol LIM ; Jaekyung CHOI ; Moran KI ; Yong Man KIM ; Jae Weon KIM ; Jea Hoon KIM ; Eal Whan PARK ; Hoo Yeon LEE ; Sung Chul LIM ; Chi Heum CHO ; Sung Ran HONG ; Ji Yeon DANG ; Soo Young KIM ; Yeol KIM ; Won Chul LEE ; Jae Kwan LEE
Journal of Gynecologic Oncology 2015;26(3):232-239
		                        		
		                        			
		                        			The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass-screening program. Furthermore, a new method has been introduced in cervical cancer screening. Therefore, the committee for cervical cancer screening in Korea updated the recommendation statement established in 2002. The new version of the guideline was developed by the committee using evidence-based methods. The committee reviewed the evidence for the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papillomavirus (HPV) testing, and reached conclusions after deliberation. The committee recommends screening for cervical cancer with cytology (Papanicolaou test or liquid-based cytology) every three years in women older than 20 years of age (recommendation A). The cervical cytology combined with HPV test is optionally recommended after taking into consideration individual risk or preference (recommendation C). The current evidence for primary HPV screening is insufficient to assess the benefits and harms of cervical cancer screening (recommendation I). Cervical cancer screening can be terminated at the age of 74 years if more than three consecutive negative cytology reports have been confirmed within 10 years (recommendation D).
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Age Factors
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Early Detection of Cancer/adverse effects/*methods/standards
		                        			;
		                        		
		                        			Evidence-Based Medicine
		                        			;
		                        		
		                        			False Positive Reactions
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Papillomavirus Infections/diagnosis
		                        			;
		                        		
		                        			Papillomavirus Vaccines
		                        			;
		                        		
		                        			Patient Selection
		                        			;
		                        		
		                        			Pregnancy
		                        			;
		                        		
		                        			Pregnancy Complications, Neoplastic/diagnosis
		                        			;
		                        		
		                        			Republic of Korea
		                        			;
		                        		
		                        			Review Literature as Topic
		                        			;
		                        		
		                        			Uterine Cervical Neoplasms/*diagnosis
		                        			;
		                        		
		                        			Vaginal Smears/adverse effects/methods/standards
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
8.Various types of total laparoscopic nerve-sparing radical hysterectomies and their effects on bladder function.
Hiroyuki KANAO ; Kazuko FUJIWARA ; Keiko EBISAWA ; Tomonori HADA ; Yoshiaki OTA ; Masaaki ANDOU
Journal of Gynecologic Oncology 2014;25(3):198-205
		                        		
		                        			
		                        			OBJECTIVE: This study was conducted to ascertain the correlation between preserved pelvic nerve networks and bladder function after laparoscopic nerve-sparing radical hysterectomy. METHODS: Between 2009 and 2011, 53 patients underwent total laparoscopic radical hysterectomies. They were categorized into groups A, B, and C based on the status of preserved pelvic nerve networks: complete preservation of the pelvic nerve plexus (group A, 27 cases); partial preservation (group B, 13 cases); and complete sacrifice (group C, 13 cases). To evaluate bladder function, urodynamic studies were conducted preoperatively and postoperatively at 1, 3, 6, and 12 months after surgery. RESULTS: No significant difference in sensory function was found between groups A and B. However, the sensory function of group C was significantly lower than that of the other groups. Group A had significantly better motor function than groups B and C. No significant difference in motor function was found between groups B and C. Results showed that the sensory nerve is distributed predominantly at the dorsal half of the pelvic nerve networks, but the motor nerve is predominantly distributed at the ventral half. CONCLUSION: Various types of total laparoscopic nerve-sparing radical hysterectomies can be tailored to patients with cervical carcinomas.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hypogastric Plexus/injuries
		                        			;
		                        		
		                        			Hysterectomy/adverse effects/*methods
		                        			;
		                        		
		                        			Laparoscopy/adverse effects/*methods
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Neoplasm Staging
		                        			;
		                        		
		                        			Pelvis/innervation
		                        			;
		                        		
		                        			Peripheral Nerve Injuries/etiology/*prevention & control
		                        			;
		                        		
		                        			Postoperative Period
		                        			;
		                        		
		                        			Urinary Bladder/*innervation/physiopathology
		                        			;
		                        		
		                        			Urodynamics
		                        			;
		                        		
		                        			Uterine Cervical Neoplasms/pathology/*surgery
		                        			
		                        		
		                        	
9.Surgical Outcomes of Robotic Radical Hysterectomy Using Three Robotic Arms versus Conventional Multiport Laparoscopy in Patients with Cervical Cancer.
Ga Won YIM ; Sang Wun KIM ; Eun Ji NAM ; Sunghoon KIM ; Hee Jung KIM ; Young Tae KIM
Yonsei Medical Journal 2014;55(5):1222-1230
		                        		
		                        			
		                        			PURPOSE: To compare surgical outcomes of robotic radical hysterectomy (RRH) using 3 robotic arms with those of conventional laparoscopy in patients with early cervical cancer. MATERIALS AND METHODS: A retrospective cohort study included 102 patients with stage 1A1-IIA2 cervical carcinoma, of whom 60 underwent robotic and 42 underwent laparoscopic radical hysterectomy (LRH) with pelvic lymph node dissection performed between December 2009 and May 2013. Perioperative outcomes were compared between two surgical groups. RESULTS: Robotic approach consisted of 3 robotic arms including the camera arm and 1 conventional assistant port. Laparoscopic approach consisted of four trocar insertions with conventional instruments. There were no conversions to laparotomy. Mean age, body mass index, tumor size, cell type, and clinical stage were not significantly different between two cohorts. RRH showed favorable outcomes over LRH in terms of estimated blood loss (100 mL vs. 145 mL, p=0.037), early postoperative complication rates (16.7% vs. 30.9%, p=0.028), and postoperative complications necessitating intervention by Clavien-Dindo classification. Total operative time (200.5+/-61.1 minutes vs. 215.6+/-83.1 minutes, p=0.319), mean number of lymph node yield (23.3+/-9.3 vs. 21.7+/-9.8, p=0.248), and median length of postoperative hospital stay (11 days vs. 10 days, p=0.129) were comparable between robotic and laparoscopic group, respectively. The median follow-up time was 44 months with 2 recurrences in the robotic and 3 in the laparoscopic cohort. CONCLUSION: Surgical outcomes of RRH and pelvic lymphadenectomy were comparable to that of laparoscopic approach, with significantly less blood loss and early postoperative complications.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Blood Loss, Surgical
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy/*adverse effects/methods
		                        			;
		                        		
		                        			Laparoscopy/*adverse effects
		                        			;
		                        		
		                        			Length of Stay
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Postoperative Complications/*epidemiology
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Robotic Surgical Procedures/*adverse effects
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Uterine Cervical Neoplasms/*surgery
		                        			
		                        		
		                        	
10.Post-Operative Hemorrhage after Myomectomy: Safety and Efficacy of Transcatheter Uterine Artery Embolization.
Alvin Yu Hon WAN ; Ji Hoon SHIN ; Hyun Ki YOON ; Gi Young KO ; Sangik PARK ; Nak Jong SEONG ; Chang Jin YOON
Korean Journal of Radiology 2014;15(3):356-363
		                        		
		                        			
		                        			OBJECTIVE: To evaluate the safety and clinical efficacy of transcatheter uterine artery embolization (UAE) for post-myomectomy hemorrhage. MATERIALS AND METHODS: We identified eight female patients (age ranged from 29 to 51 years and with a median age of 37) in two regional hospitals who suffered from post-myomectomy hemorrhage requiring UAE during the time period from 2004 to 2012. A retrospective review of the patients' clinical data, uterine artery angiographic findings, embolization details, and clinical outcomes was conducted. RESULTS: The pelvic angiography findings were as follows: hypervascular staining without bleeding focus (n = 5); active contrast extravasation from the uterine artery (n = 2); and pseudoaneurysm in the uterus (n = 1). Gelatin sponge particle was used in bilateral uterine arteries of all eight patients, acting as an empirical or therapeutic embolization agent for the various angiographic findings. N-butyl-2-cyanoacrylate was administered to the target bleeding uterine arteries in the two patients with active contrast extravasation. Technical and clinical success were achieved in all patients (100%) with bleeding cessation and no further related surgical intervention or embolization procedure was required for hemorrhage control. Uterine artery dissection occurred in one patient as a minor complication. Normal menstrual cycles were restored in all patients. CONCLUSION: Uterine artery embolization is a safe, minimally invasive, and effective management option for controlling post-myomectomy hemorrhage without the need for hysterectomy.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy
		                        			;
		                        		
		                        			Leiomyoma/blood supply/*surgery
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Postoperative Hemorrhage/*therapy
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Uterine Artery Embolization/adverse effects/*methods
		                        			;
		                        		
		                        			Uterine Neoplasms/blood supply/*surgery
		                        			;
		                        		
		                        			Uterus/blood supply/surgery
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail